safracin B Property

Boiling point:

755.1±60.0 °C(Predicted)

Density 

1.41±0.1 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

Soluble in DMSO (up to 20 mg/ml)

pka

9.75±0.70(Predicted)

form 

solid

color 

Yellow-green

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H312Harmful in contact with skin

H315Causes skin irritation

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P312Call a POISON CENTER or doctor/physician if you feel unwell.

P321Specific treatment (see … on this label).

P322Specific measures (see …on this label).

P330Rinse mouth.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P362Take off contaminated clothing and wash before reuse.

P363Wash contaminated clothing before reuse.

P501Dispose of contents/container to..…

safracin B Chemical Properties,Usage,Production

Description

Safracin B (87578-99-2) is a novel antibiotic of the saframycin family produced by?Pseudomonas fluorescens.1?Safracin B displays antitumor activity against L1210 and P388 leukemias and B16 melanoma. Compared with safracin A, the toxic and effective doses were much lower. Safracin B also prolonged the life of tumor-bearing mice to a greater extent than safracin A.2

Uses

Safracin B is a new antibiotics from the family of Safracin produced by Pseudomonas fluorescens A2-2. Safracin B is an antibiotic that exhibits anti-tumor properties.

References

1) Ikeda?et al.?(1983),?Safracins, new antitumor antibiotics. I. Producing organism, fermentation and isolation; J. Antibiot. Tokyo,?36?1279 2) Okumoto?et al. (1985),?Activity of safracins A and B, heterocyclic quinone antibiotics, on experimental tumors in mice; J. Antibiot.Tokyo,?38?767